We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

[NEW DELHI] Stroke patients do not benefit from stem cell therapy according to a new study by Indian medical scientists.

The study, published online this month (November) in American Heart Association’s journal Stroke, involved multi-centre, randomised trials on 120 moderately acute stroke patients who were intravenously injected with hematopoietic stem cells (HSCs) that give rise to other blood cells and are located in the bone marrow.
Lead author of the study and head of neurosciences at the All India Institute of Medical Sciences (AIIMS), Delhi, Kameshwar Prasad, tells SciDev.Net that the treatment was not any more effective than the usual regime for stroke patients in a control group.

Researchers and patients in the trials were spread over five government hospitals including AIIMS, Air Force Medical College, Pune, Post Graduate Institute of Medical Education and Research, Chandigarh, Army Hospital, Delhi, and Sanjay Gandhi Post-graduate Institute of Medical Sciences, Lucknow.
While 60 patients forming the control group were placed on conventional treatment, another 60 were additionally injected with stem cells taken from their bone marrow.
Patients chosen for the study averaged 52 years of age and had suffered stroke between one and four weeks before they were put on treatment. Their difficulties in using upper and lower limbs were measured at three, six and 12 months and the results were nearly the same in both groups.
The randomised trials, funded by India’s Department of Biotechnology, started in June 2010 after pilot studies showed promise. The trials ran until 2012.
Prasad said the Indian study, the first ever-randomised trial using stem cells in stroke patients, removes all assumptions about stem cells being a remedy for stroke patients. “This study should be a warning to desperate patients who get cheated by private clinics,” he said.  

“Until ongoing or further randomised trials show efficacy this treatment should not be used in clinical practice and patients should not accept such therapy without question,” the study concludes.

Sujata Mohanty, assistant professor in the stem cell facility of AIIMS and study participant says the findings do not write off the potential of hematopoietic cells in stroke treatment for further research. 

There are other ways to explore their potential than the ones we opted for, Mohanty says. “We opted for the intravenous route for instance and we delayed treatment by more than a week,” she tells SciDev.Net.

> Link to the study in the journal Stroke.

This article has been produced by SciDev.Net's South Asia desk.

Related topics